DOCSLIB.ORG

NIHAA Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Newsletter of the NIH Alumni Association Spring 1999 Vol. 11 , No. 1 date Lively Debate Warms Award, Meeting, Lecture ACD Meeting Morella, Henney, Choppin Slated for NIHAA Events By Ricli McMa1111s In 1999. the NIH A lumni Association commissioner, ..-i ill be the featured will host two important events. rirst, speaker. Then in th e fall, Dr. Purnell Last December's meeting of the Rep. Constance W. Choppin. advisory commiuee to the NIH A. Morella (R­ president of the director was a 101 like th e unusual M d.) will be Howard Hughes weather the week ii was conducted-a honored with M edical Instirute, tad holler than anyone expected. the 1999 will deliver the third While it included. early in 1he agenda. NIHAA Public James A. Shannon a winning synopsis of progress in the Service Award Lecture on Wednes­ Human Genome Proj ect delivered by at the NIHAA day, Nov. 17. at 3 N HGRI director Dr. Francis Collins. annual meeting p.m. in M asur who reviewed the ambitious scope of that will be held Auditorium. the institute's new 5-year plan. the on June 12. In Rep. Morella was next two topics-plans for an "NLH addition. Dr. reelected in 1998 to Academy:· including a degree-granting Jane E. Henney. graduate school. and a revisiting of the new FDA Rep. Constance A. Morella (R·Md.) (see Even1s. p. 2) last summer's Institute of Medicine report on priority-setting at N lH­ provoked passions around the table. Generous '99 Budget; Small 2000 Projection Deliberations were further enlivened Dec. 3 by the presence of special By Rich McMa1111s Enacted in Public Law I05-277. the invitees including Katherine Graham. budget also brings new entities and chair of the Wc1slii11gto11 Post executive While there have been larger percent­ names to the campus., including new commiuee. age increases in NJ H's budget in (See Budgets, p. 14) The meeting al ways starts with a decades past- mostly during 1he State of the N IH overview by th e Shannon era in the early sixties, when director. which ranges from personnel new institutes began prolifera 1.ing-1hc In This Issue Pagt' announcements to from-burner policy $2.03 billion addition to the FY I998 Re.f£•mr:h Fes1iw1l '98 3 issues; Dr. Harold Yarmus cautioned at level signed by President Clinton on the outset lhat there were "quite a few Oct. 2 1 is by far the largest dollar Calendnr 4 diverse and controversial topics" on increase in agency history. The 14.9 News from and abo111 NIHAA members 5 the agenda. Having testi lied the day percent bump-up brings the FY 1999 beforl! at a Senate hearing on research appropriation Lo $15 .652 billion. a RM£•11herg delfrers Shan11011 lec111re /0 involving embryonic stem cells, figure hailed jubilantly in all corners Science Research Updntes 16 Varmus lirst had to endure some good­ of the agency. natured ribbing from colleagues who "This degree of confidence in N IH R& W 1imeli111! 18 had seen news coverage describing the by the Congress. the administration '·eloquence" of the testimony at the and the American people brings with it Framingham s1111{1• annfrersary 19 hearing. a special responsibility to continue the FYI 20 Among highlights from 1he year-in­ high quality research traditions at N IH review was news th at Varmus is laboratories and among our grantees. Nill Noles 22 "negotiating with what I hope will be and to ensure the highest quality of [\/ail-ill bn/101 f(Jr board 29 the final candidate" to head the new adminisrration of these funds.'' said j Vaccine Research Center at N IH. Tony ltteilag, NLH deputy director for Nil1 Re1msper1il•es 31 (See Meeting p. 12) management. N I H A A U P D A T E Events ( comin11ed from p. I ) a seve111h term for the 8th Congres­ first woman to b~ appointed as FDA Update sional district. an area that includes commjssioner. Henney was deputy Tile 'lliAA Update is the newsleuer oftile the NIH campus. director of NCI ( and aJso 1980-1985) NIH Alumni Association. The NIHAA office Her selection as this year·s awardee a medical oncologist at the institute is at 9101 Old Georgetown Rd.. Bethesda. was based on her continuing, compre­ ( 1975-1985). She was the deputy MD 20814-1616. 301-530-0567. hensive and strong support for NIH commissioner for operations ( I 992­ and her prompt and unfailing respon­ 1994) under former FDA commis­ Editor's Note siveness to contacts on behalf or the sioner, Dr. David Kessler. The Nll-IAA Update welcomes leuers a11d institution. Maintainjng her well­ Henney left that position 10 become 11ell'S from its readers. \Ve wish to /Jro1•ide established reputation for independent vice presidenc of the University of New 11ell's abom NIH to its alumni and to thought and action as a member of Mexko Health Sciences Center. where report tilumni concems and i11formmio11­ Congress. her support for NIH is she supervised the medical school. the appoi111mems. honors. publicmions a11d tempered by her sense of public college of phannacy and several other i111eresti11g de1·elopmems-to their colleagues. If you hm•e news a bow yourself responsibility in probing for the teaching hospitals. or other alumni or commemslsuggestio11s justification and authenticity of any The NIHAA annual meeting will forthe NIl-I AA Update. please drop t11101e to request for assistance. also include a short business meeting the editor. We resen·e the right to et/ii Further, her committee assignments and an announcement of new officers m(lferials. on Governmem Reform and Oversight and newly elected members of the Editor: Harriet R. Greenwald and on Science have provided a basis board. for deep understanding of the role of Details about the Shannon lecture NIHAA Newsletter Editorial Advisory a federal agency in the nation's will be in the summer issue of the Committee cientilic aspirations and policies. NIHAA Update. As part of the annuaJ meeting Invitations to both events will be Jerome G. Green. Chaimwn Ar1rice B"der program. NfHAA members will meet mailed to members in the spring Michael M. Gouesman and hear from Dr. Jane Henney. the and faJl . Victoria A. Harden C"rl l..e11emlwl Robert G. Martin Abner Louis Notki11s Two Upcoming NIHAA Events Saul Rosen Storm Whaley Richard G. \Vyau NIHAA News/el/er Board of Contributing Editors A1111ual Meeting and Pamela E. Anderson Public Service Award James A. Sha11110T1 Lecture Wednesday, Nov. 17, I 999 Unda Brown Saturday, June 12 Giorgio Bernardi 3 10 a.m. - noon p.m. H. Franklin Bunn The Mary Woodard Lasker Center Masur Auditorium Henryk J!ise11ber11 Bldg. 10 Donald S. Fredrickson (Bldg. 60) 0 11 the NIH Campus u1rs A. Ha11so11 Reception Following George Klein Light Refreshments Richard M. Kmuse Robert Q. Marston Richard McMa1111s Carlos Monge Roger Monier Seymour Perry Lois A. Sa/::.J11a11 Michael Sela 2 SPRING 1 9 9 9 NIHAA Officers Research Festival '98 a Big Draw William S. Jordan, Jr., President William I. Gay, Vice President It was as if some giant had grabbed But that sentiment, combined with Jerome G. Green. Vice Presidell/ the NIH campus by the corner up near leaden skies for two of the fes tival's Storm Whaley, Secre/(/ryffreasurer the firehouse on Old Georgetown Rd. three days, did nothing to dampen the Past Presidents and Lilted it so that everything slid enthusiasm of attendees. one of whom, helplessly toward the Natcher Bldg. NIH director Dr. Harold Varmus. Calvin 8. Baldwin. Jr.. President 1995-1997 Oct. 6-9 as the 12th Research Festival exited the apoptosis session beaming Thomas J. Kem1ed11, Jr. drew many hundreds of NlH'ers to a and waving, invigorated, not President 1993-i 995 ravishing feast of intramural science. bedimmed, by his encounter with the Joe R. Held. Preside/I/ 1991- 1993 For 3 days, Natcher and its environs biological enforcers of cells' demise. Gordon D. Wallace. Presidem 1990- 1991 were to science what Bethesda is to Teetering, perhaps unironically. Board of Directors restaurants-a teemiJ1g smorgasbord of between the opening session on life's Carl C. Baker tas ty possibilities. cosmic origins and the final. apoptotic W. Emmel/ Barkley It became almost comical, after a day (if not apocalyptic) session, was \Vil/iam R. Carroll or two. to see hundreds of pre-, post­ " Insight from the Bedside,'' which Belia l. Ceja and postpostclocs fleeing the crowded offered hope for the still-living, Peter Condl(ffe John L Decker morning plenary sessions for one of including insights into AIDS pathogen­ Murray Eden dozens of workshops held in various esis and description of a new vaccine Carl Fre11s nooks and warrens within the sprawl­ 10 prevent severe diarrhea in infants Murra\' Goldstein ing Natcher complex. aml youngstt:rs. Samuel W. Greenhouse All adopted postures of predicament Por those addled by the possibilities. Mary Calley Hartman Joe R. Held as they scanned the glossy 83-page there were massive tents outside the Joseph Keyes, Jr. menu of choices. brows knit in Natcher center offering diversions of a Lloyd W. UM concentration. What if, by chance, sort: on the southeast side were two Teny l. Lierman you were interested in both "Charac­ tents housing the Technical Sales Lois F. Lipsett terization of Biologic Mediators by Association's annual exhibit of Walter Magruder Carolyn McHale Spectroscopic M ethods" and "Gene scientific equipment, and to the Charles Miller. II Regulatory Proteins," both lighting for northwest sat a picnic tent, including a Paul D. Parkman your attention from 10:30 a.m. LO half stage where some intramural perform­ Joseph Perpich past noon on the festivar s last day? ers entertained.
Recommended publications
  • T. Franklin Williams Scholars Program

    T. Franklin Williams Scholars Program

    Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M.
  • Journal Pre-Proof

    Journal Pre-Proof

    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
  • HIV?AIDS Researchers at the NIH Clinical Center

    HIV?AIDS Researchers at the NIH Clinical Center

    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The

    That Record-Breaking Sprint to Create a COVID-19 Vaccine The

    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
  • Nci-Plan-2013.Pdf

    Nci-Plan-2013.Pdf

    THE NATIONAL CANCER PROGRAM MANAGING THE NATION’S RESEARCH PORTFOLIO AN ANNUAL PLAN AND BUDGET PROPOSAL FOR FISCAL YEAR 2013 National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Contents 1 Foreword 4 Provocative Questions 8 Center for Cancer Genomics 16 Introduction to Cancer Profiles 18 Pancreatic Ductal Adenocarcinoma 22 Colorectal Cancer 26 B-Cell Lymphoma 30 Renal Cell (Kidney) Cancer 34 GI Stromal Cancer 39 Research Focus: Comorbidities 42 Research Focus: Circulating Tumor Cells 44 Research Focus: Reducing Cancer Health Disparities 50 The Frederick National Laboratory for Cancer Research 61 Small Business Innovation Research, Small BusinessTechnology Transfer (SBIR, STTR) 66 NCI Center for Global Health 72 NCI-Designated Cancer Centers 83 Glossary of Terms 84 Budget FOREWORD The National Cancer Program MANAGING THE NATION’S RESEARCH PORTFOLIO his year marks the 75th anniversary of the founding of the National Cancer Institute, the first so-called “categorical institute” of what has become the National Institutes of Health, with its 27 Institutes and Centers. Over the years, the Congress and the public have generously supported the TNCI—and the NIH generally—with sustained budgetary increases. This was especially true for the NCI during the rapid expansion of its budget following the National Cancer Act of 1971 and for the NIH, including the NCI, during the 5-year doubling of its budget, launched in 1998. Both of these eras of rapid growth were remarkably fruitful. The first launched the pursuit of cancer genes and the molecular basis of oncogenesis, laying the foundation for the transformation of clinical oncology that is now occurring.
  • NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers

    NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers

    The Newsletter of the L NIH Alumni Association Summer 1999 Vol. 11, No. 2 date NIHAA Members Enjoy June Annual Meeting with Henney, Morella Alumni attendi ng the 1999 annual meeting of the NIH.AA were given a first-band briefing on FDA by Dr. Jane E. Henney, the receml y appointed FDA commissioner. Tbe audience also participated in a question and answer exchange witb Rep. Constance A. Morella (R-Md.), who was presented with tbe NIHAA 1999 Public Service Award. Almost I00 alumni attended the June 12 morning meeting at the Mary Woodard Lasker Center on the NIH campus. Henney, wbo was NCI deputy director for five of her lO years at NIH (1985-1995) spoke infonnalJy on some of FDA's principal concerns at this time: the agency's efforts to speed Shown at the NIHAA annual meeting are (from I} NIH alumna Dr. Jane E. Henney, FDA up review without sacrifice of quality commissioner, who spoke on "Back Home Again via Indiana, Kansas and New Mexico," and safeguards; tbe need for recruiting Dr. John F. Sherman, Rep. Constance A. Morella (R-Md.), who received the 1999 NIHAA Public Service Award, and Dr. William S. Jordan, Jr., outgoing NIHAA president. (see A flflual Meeting, p. 12) Director's Advisors Bat 6 for 7 in June Meeting In This Issue Page Choppin To Give Third Research Festival '99 J By Rich McManus NIHAA Shannon Lecture Ca/e11dar 5 The scorecard at the end of a daylong Dr. Purnell W. Cboppin, president of .News .from a11d about Nlf/A;/ me111be1:r (f session of lhe advisory committee to the Howard Hughes Medical lnstirure, the NIH director (ACD) on June 3 read A le11erjro1111he 11e111 Nlf/AIJ preside111 IO will deliver the third James A.
  • Study Protocol, Including Amendment

    Study Protocol, Including Amendment

    Document Type: Study Protocol, including Amendment (Informed Consent Template located in Appendix I of the Protocol Version 1.0 and Version 2.0) Official Title: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults NCT Number: NCT03478891 Document/Date: Protocol Amendment Version 2.0: April 6, 2018 Protocol Version 1.0: February 21, 2018 Version 2.0 April 6, 2018 VACCINE RESEARCH CENTER Protocol VRC 608 (NIH 18-I-0069) A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF A HUMAN MONOCLONAL ANTIBODY, VRC-EBOMAB092-00-AB (MAB114), ADMINISTERED INTRAVENOUSLY TO HEALTHY ADULTS Study Product Provided by: Vaccine Research Center (VRC) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, MD Clinical Trial Sponsored by: NIAID/VRC/NIH, Bethesda, Maryland IND 138,090 Sponsored by: VRC/NIAID/NIH, Bethesda, Maryland Principal Investigator: Martin Gaudinski, MD VRC/NIAID/NIH Bethesda, MD 20892 IRB Initial Review Date: January 8, 2018 PRODUCT: VRC-EBOMAB092-00-AB (MAb114) PROTOCOL: VRC 608, VERSION 2.0 PROTOCOL DATE: APRIL 6, 2018 TABLE OF CONTENTS Page ABBREVIATIONS....................................................................................................................... 5 PRÉCIS.......................................................................................................................................... 8 1. INTRODUCTION............................................................................................................
  • See the Vaccine Research Center Brochure

    See the Vaccine Research Center Brochure

    Vaccine Research Center NIAID National Institute of Allergy and Infectious Diseases U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Letter from John R. Mascola, M.D., NIAID Vaccine Research Center Director, and Anthony S. Fauci, M.D., NIAID Director The Dale and Betty Bumpers Vaccine Research Center (VRC) was created by Presidential Executive Order in 1997 to accelerate the development of a vaccine directed against the devastating global pandemic caused by HIV. The VRC began its vital HIV work in 2000 and has since further expanded its scope and capabilities to combat other high-burden diseases such as influenza, respiratory syncytial virus (RSV), malaria, and tuberculosis, as well as biodefense threats and emerging infectious diseases, including Ebola, chikungunya, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), West Nile, and Zika. As an intramural research arm of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), the VRC is led by an integrated team of specialists in various disciplines, including immunology, virology, structural biology, and bioengineering. By encompassing these scientific disciplines under one roof, together with the capability to conduct human clinical trials, the VRC accelerates the process of scientific discovery leading to the design and development of prototype vaccines and biologics to protect against infectious diseases. The VRC operates as the closest analog at NIH to a private
  • Vaccine Research Center, NIAID, NIH

    Vaccine Research Center, NIAID, NIH

    4/17/2018 PIPELINE OF HIV MONOCLONAL ANTIBODIES FOR PREVENTION OF HIV Session on Antibody‐Mediated Prevention 2018 Global Vaccine and Immunization Research Forum (GVIRF) 20‐22 March 2018 Bangkok, Thailand Barney S. Graham, MD, PhD Deputy Director Vaccine Research Center, NIAID, NIH Dale and Betty Bumpers Vaccine Research Center Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health 2017 VRC Principal Investigators and Program Directors 1 4/17/2018 VRC Research & Development: From AIDS to Zika August 2000 AIDS/HIV Chikungunya Ebola/Marburg Influenza Malaria MERS-CoV, SARS RSV Smallpox Tuberculosis W/E/V equine encephalitis viruses West Nile virus, Zika Engineering Lab Pilot Plant Vaccine Evaluation Clinic Immunology Lab Partners for Advanced Development Functional Activity of Anti-Viral Antibodies • Neutralization – Aggregation – Attachment blocking – Cleavage inhibition – Fusion inhibition – Preventing particle release • Fc‐mediated functions – Antibody dependent cell‐mediated cytotoxicity (NK, Macrophage, Neutrophil) – Complement binding and activation • Opsinization and clearance by non‐susceptible cells • Blocking pathogenic immunomodulatory molecules 2 4/17/2018 Long History of Using Antibodies to Treat Infectious Diseases (Serum Therapy) Shibasaburo Kitasato 1890: Emil von Behring and Shibasaburo Kitasato worked on “anti‐ toxins” for tetanus and diphtheria that led to concept for serum therapy 1901: Emil von Behring ‐ 1901 Nobel Prize in Physiology or Medicine “For his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of Wernicke, Frosch, and medical science and thereby placed in the hands of the physician a Behring in Koch’s Berlin Lab victorious weapon against illness and deaths".
  • Conversations with Mike Milken

    Conversations with Mike Milken

    CONVERSATIONS WITH MIKE MILKEN Francis Collins Director, National Institutes of Health April 3, 2020* Mike Milken: Good morning, Francis. Francis Collins: Good morning, Mike. One of the things we learned many years ago is that to accelerate science, one of the keys was collaboration. Could you talk a little bit about how you feel collaboration is working today? Well, it is critical, especially at a time of global pandemic with COVID-19 that we see around us. For me, having come up through scientific experiences like the Human Genome Project and various things that followed after that, all of which are intensely collaborative, it’s natural to look at “Are we really doing everything we can this situation and say, are we doing in this moment of global crisis to knock enough to bring together all of the down barriers and accelerate progress?” best and brightest; all the talent; all the resources from every sector; from academia; from NIH; from industry, both pharma and biotech; from philanthropy; This interview has been lightly edited for clarity and readability. Conversations with Mike Milken 1 Conversations with Mike Milken: Francis Collins, April 3, 2020 from stakeholders of all sorts; from the regulators? Are we really doing everything we can in this moment of global crisis to knock down barriers and accelerate progress? So that's where my head is this morning, sequestered as I am in my home office trying to behave the way we all should be in terms of distancing, but trying to light a fire under any kind of opportunity here to speed up the process of identifying effective treatments and vaccines and making sure our clinical trials are ready and tuned up, to try out virtually all of the good ideas that come along.
  • Paving the Road to an HIV Vaccine

    Paving the Road to an HIV Vaccine

    Paving the Road to an HIV Vaccine: Employing Tools of Public Policy to Overcome Scientific, Economic, Social and Ethical Obstacles Michael Langan and Chris Collins Monograph Series December 1, 1998 Center for AIDS Prevention Studies AIDS Research Institute University of California, San Francisco This research was supported by the National Institute of Mental Health, National Institutes of Health, grant number MH42459. PAVING THE ROAD TO AN HIV VACCINE TABLE OF CONTENTS PREFACE..........................................................................................................................................3 THE GLOBAL TRAGEDY OF HIV DEMANDS A PREVENTATIVE VACCINE .......................................4 NEW GOVERNMENT PROGRAMS AND FUNDS ..................................................................................5 National Institutes of Health.........................................................................................................5 NIH AIDS Research Program Evaluation Task Force ....................................................................5 AIDS Vaccine Research Committee.............................................................................................5 NIH Office of AIDS Research.......................................................................................................6 Vaccine Research Center............................................................................................................6 The National Institute of Allergy and Infectious Diseases...............................................................6
  • Annual Report FY 2020

    Annual Report FY 2020

    NIH Technology Transfer Annual Report FY 2020 FY 2020 NIH Technology Transfer Annual Report 1 TABLE OF CONTENTS Introduction .............................................................................................................. 4 Mission Statement ................................................................................................... 5 Inventions and Agreements ................................................................................... 6 Institute and Center Updates .................................................................................. 9 NCATS - National Center for Advancing Translational Sciences ............................................. 9 NCI - National Cancer Institute................................................................................................11 NHGRI - National Human Genome Research Institute .......................................................... 16 NHLBI - National Heart Lung and Blood Institute ................................................................... 18 NIAID - National Institute for Allergies and Infectious Diseases ............................................. 22 NIDDK - National Institute of Diabetes and Digestive Diseases ............................................ 26 NIEHS - National Institute of Environmental Health Sciences ............................................... 27 NIMH - National Institute of Mental Health ............................................................................. 29 NINDS - National Institute of Neurological Disorders